Zealand Eyes Opportunities In Burgeoning Obesity Market
Boehringer-Partnered Drug Moving Into Phase III Soon
Given the renewed interest in the commercial potential of obesity therapies, Zealand is heralding the potential of its treatments for the overweight.
